Literature DB >> 9760218

WHO cytokine standardization: facilitating the development of cytokines in research, diagnosis and as therapeutic agents.

A R Mire-Sluis1, R G Das, A Padilla.   

Abstract

The development and widespread application of recombinant DNA technology has dramatically increased the number of cytokines available for clinical evaluation. New and novel cytokines are being discovered, cloned and entered into clinical trials at such a rate that it is often the case that the biological activities of these proteins are poorly understood during their development as therapeutic agents. In addition, manufacturers of any one cytokine can produce the protein from different cellular sources resulting in materials that exhibit markedly different specific activities. When estimating the amount of biological activity of different preparations with different specific activities by bioassay, mass units cannot be used and biological activity is therefore expressed as 'biological potency units'. The biological unit requires definition by a standard that is assay-independent (especially when measuring a particular type of biological activity). In many cases, a variety of assay methods will be available and the material chosen for a standard should ideally be suitable for use with as many of them as possible. Once the unit is defined, this can be used in any laboratory, thus providing a means of ensuring uniformity throughout the world in the designation of potency of different biological preparations. The World Health Organisation (WHO) standardization programme involves the production of biologically stable, well characterised potency and immunoassay standards that are available world-wide using a single international unitage. Over the years, WHO international standards have been used to dramatically reduce the variation in estimates of cytokine preparations within and between laboratories for immunoassays and bioassays. WHO international standards are primary reference preparations against which secondary, or working standards (including regional standards, national standards, pharmacopoeial standards and in-house working standards) can be calibrated.

Mesh:

Substances:

Year:  1998        PMID: 9760218     DOI: 10.1016/s0022-1759(98)00073-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

Review 1.  Progress in the use of biological assays during the development of biotechnology products.

Authors:  A R Mire-Sluis
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

Review 2.  Equivalence studies for complex active ingredients and dosage forms.

Authors:  Lokesh Bhattycharyya; Roger Dabbah; Walter Hauck; Eric Sheinin; Lynn Yeoman; Roger Williams
Journal:  AAPS J       Date:  2005-11-17       Impact factor: 4.009

Review 3.  Guiding the vaginal microbicide trials with biomarkers of inflammation.

Authors:  Raina N Fichorova
Journal:  J Acquir Immune Defic Syndr       Date:  2004-10       Impact factor: 3.731

4.  Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation.

Authors:  J L Fahey; N Aziz; J Spritzler; S Plaeger; P Nishanian; J L Lathey; J Seigel; A L Landay; R Kilarui; J L Schmitz; C White; D W Wara; R Akridge; J Cutili; S D Douglas; J Reuben; W T Shearer; M Nokta; R Polland; R Schooley; D Asthana; Y Mizrachi; M Waxdal
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

5.  Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial.

Authors:  Nisha Mangalat; Yuying Liu; Nicole Y Fatheree; Michael J Ferris; Melissa R Van Arsdall; Zhongxue Chen; Mohammad H Rahbar; Wallace A Gleason; Johana Norori; Dat Q Tran; J Marc Rhoads
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

6.  Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study.

Authors:  Raina N Fichorova; Nicola Richardson-Harman; Massimo Alfano; Laurent Belec; Cedric Carbonneil; Silvia Chen; Lisa Cosentino; Kelly Curtis; Charlene S Dezzutti; Betty Donoval; Gustavo F Doncel; Melissa Donaghay; Jean-Charles Grivel; Esmeralda Guzman; Madeleine Hayes; Betsy Herold; Sharon Hillier; Carol Lackman-Smith; Alan Landay; Leonid Margolis; Kenneth H Mayer; Jenna-Malia Pasicznyk; Melanie Pallansch-Cokonis; Guido Poli; Patricia Reichelderfer; Paula Roberts; Irma Rodriguez; Hela Saidi; Rosaria Rita Sassi; Robin Shattock; James E Cummins
Journal:  Anal Chem       Date:  2008-05-17       Impact factor: 6.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.